Quotient Sciences, a leading drug development services organisation, has significantly expanded its formulation development and clinical trial manufacturing operations at its Reading, UK, facility. The programme’s investment has tripled the site’s GMP capacity, added new equipment for solid oral dose manufacturing and significantly increased staffing levels.
“Our investment in Reading is in direct response to increasing client demand,” said Mark Egerton, CEO of Quotient Sciences. “With drug development expertise on both sides of the Atlantic, we are optimally positioned to serve our global client base. The Reading site can support customers with stand-alone formulation and clinical trial manufacturing services that can also be integrated into Translational Pharmaceutics programmes.”
Activities at the 48000-square-foot Reading facility are focused on small molecule drug products for oral and inhaled delivery spanning drug substance characterisation, formulation development and clinical trial manufacturing. The site routinely handles poorly soluble compounds and is equipped with a broad range of technologies including spray drying, hot melt extrusion, lipidic systems and micronisation.
Its capacity is bolstered by 13 GMP manufacturing suites to support traditional Phase I-III clinical trial manufacturing and Translational Pharmaceutics programmes that integrate real-time adaptive manufacturing and clinical research. This flexible and nimble approach allows batch sizes to be tailored to the precise needs of a clinical trial. Drug products are rapidly supplied into global patient trials and clinical pharmacology units, delivering substantial benefits to customers including flexible dose adjustments, reductions in manufacturing costs and shorter manufacturing lead times.
